SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is a top trending stock as investors analyze its J.P. Morgan Healthcare Conference presentation for critical updates on its oral VK2735 program and commercialization plans, reinforced by a recent Chief Commercial Officer hire and the completion of its obesity maintenance study enrollment. The community is sharply divided between bullish expectations for a significant partnership or buyout, driven by the drug's perceived 'best-in-class' potential, and concerns over stock price suppression and management's strategy within the highly competitive metabolic market.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid discussions surrounding potential new tariffs on countries trading with Iran and a reported DOJ probe into Fed Chair Powell, sparking debate on market stability and the independence of the central bank. Despite these headlines, a strong bullish sentiment prevails among many, emphasizing buying opportunities during dips and highlighting the market's resilience. The community is actively discussing whether the market can sustain its upward momentum given these geopolitical and regulatory concerns, often with frustration from those anticipating a significant pullback.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending due to strategic announcements around its ambitious "Meta Compute" AI infrastructure buildout, which includes securing multi-gigawatt nuclear energy agreements to power future data centers. This aggressive AI push, alongside reported layoffs in the Reality Labs division, is sparking mixed community reactions regarding the scale of investment versus potential returns. Investors are keenly observing these developments as Meta intensifies its position in the global AI race, with many awaiting further clarity on the long-term vision.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is trending sharply lower following the FDA's request for additional clarification on the clinical benefit of FILSPARI for FSGS, a development that has caused significant market jitters ahead of its PDUFA decision. While many in the community are concerned this signals a potential Complete Response Letter, a notable counter-narrative suggests the sell-off is an overreaction, pointing to the company's strong commercial execution for FILSPARI in IgAN and solid financial standing as reasons to buy the dip.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy (IMSR) is trending due to a significant U.S. Department of Energy (DOE) agreement for Project TETRA, fast-tracking the development and operation of its Integral Molten Salt Reactor (IMSR) pilot. This news has reignited community discussions, with many comparing IMSR favorably to peers like OKLO and highlighting its advanced molten salt technology for meeting growing energy demands, particularly from AI data centers. Investors are optimistic about the DOE agreement as a crucial de-risking catalyst for the stock and the broader advanced nuclear sector.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending due to a new partnership and pre-production order with a major U.S. defense contractor, fueling anticipation for a substantial contract to supply advanced computing systems for Army combat vehicles. The community is buzzing with discussion about the immense potential in edge AI and defense, viewing OSS as significantly undervalued with a tight float and strong growth prospects in AI infrastructure, especially after a strategic asset sale to sharpen its focus.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending due to anticipation surrounding its upcoming JPM Healthcare Conference presentation and updated investor materials, which highlight strategic directions including a new 12% market share in Japan. Community discussion is heavily focused on the company's substantial short interest, sparking speculation of a potential short squeeze, while also voicing strong calls for management to secure significant partnerships or a buyout to unlock the value of its vaccine technology.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is a focal point of discussion following a substantial stock price correction, as investors weigh a CFO transition and positive preliminary Q4 user growth against broader concerns. The community is sharply divided, with bulls highlighting the company's strong user engagement, expanding product offerings, and perceived undervaluation, especially after a recent analyst upgrade. Conversely, bears express skepticism over Duolingo's long-term viability in the face of rapidly advancing AI technologies and question management's focus on user growth over immediate profitability.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending amid intense community debate, fueled by its ongoing underperformance and deep frustration with current management's ability to deliver sustained profitability. However, many investors remain bullish, highlighting the company's position as a global leader in virtual care and its potential to capture a significant share of the rapidly expanding AI healthcare market. Recent partnerships, such as with TytoCare for at-home diagnostics, and anticipation around the $50 billion Rural Health Transformation Program are seen as key catalysts, driving speculation of a significant long-term rebound for the stock.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as the U.S. recommendation to add Duchenne Muscular Dystrophy to the newborn screening panel significantly broadens the long-term market for its Elevidys gene therapy. While recent preliminary financial updates led to stock volatility, the community is actively discussing perceived undervaluation and the substantial pipeline potential, particularly in light of expanding early patient identification.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>On Dec. 31, 2025, INBS stock closed over 132% after announcing a manufacturing partnership with Syrma Johari MedTech.</li><li>The company also announced a private placement with two healthcare-focused institutional investors to issue 2.3 million shares of common stock.</li><li>Intelligent Bio Solutions had announced a 1-for-10 reverse stock split effective Dec. 15.</li></ul>Shares of Intelligent Bio Solutions (INBS) have seen strong buying interest in recent weeks, with the stock adding more than 35% in premarket trading on Monday.&nbsp;From the close on Dec. 30, 2025, to Jan. 9, 2026, <a href="https://stocktwits.com/symbol/INBS">INBS stock</a> has surged about 337%, breaching both its 50-day moving average (50-DMA) and the longer-term 200-DMA during the rally.This stellar rally has made it a momentum favorite among retail traders, driven by a recent manufacturing partnership, fresh capital boost, and a compliance update with Nasdaq; however, concerns around dilution and its volatile ride continue to temper sentiment.&nbsp;<h2 class="st-heading-2">What Led To INBS Rally?</h2>On Dec. 31, 2025, INBS stock closed over 132% after announcing a manufacturing partnership with Syrma Johari MedTech to scale production of its fingerprint drug-screening reader. The deal is expected to cut annual production costs by over 40% and lift gross margins by about 20 percentage points, while expanding manufacturing capacity fourfold, Intelligent Bio Solutions said. The company said the deal positions it well for its U.S. market launch in 2026.The company also announced a private placement with two healthcare-focused institutional investors to issue 2.3 million shares of common stock along with Series K-1 and K-2 warrants for the same number of shares at $4.35 each, raising around $10 million before fees. The warrants have an exercise price of $4.10 per share.Separately, on January 7, Intelligent Bio Solutions was notified by Nasdaq that it had regained compliance to trade on the Nasdaq Capital Market. The closing bid price of INBS stock had remained at $1.00 or higher for 14 consecutive business days, from Dec. 16, 2025, to Jan. 6, 2026. The company had announced a 1-for-10 reverse stock split effective Dec. 15.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the bullish premarket movement, retail sentiment on Stocktwits remained in the ‘neutral’ zone over the past 24 hours. INBS was among the top-trending tickers on Stocktwits at the time of writing.One user thinks short interest is extremely high and predicts the stock could fall to $15. It is currently trading at $24.2.<stembedurl>https://stocktwits.com/Harsh1210/message/641505295</stembedurl>However, another user sees a setup that pits the company’s operational progress against short-term dilution fears.<stembedurl>https://stocktwits.com/Atdanaiw/message/641502687</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/silver-gold-record-highs-analyst-michael-oliver-predicts-500-breakout/cmU9UNvR4Ec">Silver’s Next Move Could Be Explosive: Michael Oliver Sees $200–$500 Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

INBS Stock Has Surged Over 330% So Far In January – But Retail Traders Are Warning Of A Pullback 

INBS shares were up more than 35% in premarket trading on Monday and were among the top trending tickers on Stocktwits.

INBS Stock Gains Triple-Digit Rally So Far In January: What’s Driving The Surge And What Traders Are Saying

Equity

Why Intelligent Bio Solutions Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session

INBS Stock Surges 132.4% on New Manufacturing Partnership 

Intelligent Bio Solutions' stock jumps after a new manufacturing partnership aimed at cutting costs, boosting margins and scaling production ahead of U.S. expansion.

Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026 Baidu, Rubico, Intelligent Bio Solutions In Focus

U.S. stock futures rose on the first trading day of the year on Friday after missing the Santa Claus rally over the truncated week. Futures of major benchmark indices were higher. The Santa Claus...

<ul class="summary-bullets"><li>Retail sentiment improved for SPY and QQQ on Stocktwits.</li><li>Traders are eyeing Tesla’s delivery data and a surge in silver prices.</li><li>Baidu drew retail attention after its chip unit filed for an IPO.</li></ul>U.S. stock futures were trading higher early Friday as markets reopened for the first full trading session of 2026. Wall Street is looking to break a three-year streak of opening-day losses. The S&amp;P 500 has had a negative close on its first trading day&nbsp;in each of the last three years (2023-2025).As of 2:50 a.m. ET on Friday, Nasdaq 100 futures were up 0.7%, S&amp;P 500 futures rose 0.4%, and the Dow futures gained 0.1%, while Russell 2000 futures rose 0.4%.On Stocktwits, the retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, moved to ‘bullish’ from ‘neutral’ a day ago. And sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bullish’, amid low message volumes.&nbsp;<h2 class="st-heading-2">Trending Stocks To Watch</h2> Baidu (BIDU): Trending following news that its chip unit filed for an IPO, sparking a renewed interest in ‘China AI’ discount plays. Tesla (TSLA): High search volume and social chatter ahead of its Q4 delivery report expected today. Meanwhile, reports suggest that China’s BYD has officially dethroned it as the global EV king for the full year 2025. NIO is trending high on Stocktwits as well.&nbsp; Watch out for&nbsp;iShares Silver Trust (SLV):&nbsp;Silver jumped 2.5% in early trading, building on its best annual performance since 1979.Stellantis (STLA): The company is resurrecting a gas-powered Ram pickup truck, the TRX, with a V-8 engine, as it faces fewer federal emissions regulations, CNBC reported.Other noteworthy tickers trending on Stocktwits at the time of writing were Intelligent Bio Solutions (INBS), BigBear.ai (BBAI), Corcept Therapeutics (CORT), and Sensei BioTherapeutics (SNSE).&nbsp;<h2 class="st-heading-2">Other Catalysts To Watch</h2>On the economic front, investors are looking ahead to the release of the Fed Balance Sheet (4:30 PM ET). Markets will be eyeing updates on ‘Quantitative Tightening’ (QT) pacing. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Point To Strong New-Year Open On Wall Street: Why TSLA, BIDU, SLV, STLA Are On Traders' Radar Today

Wall Street is hoping to break a three-year streak of opening-day losses.

Top Medical Stocks To Consider - January 1st

Eli Lilly and Company, UnitedHealth Group, Intelligent Bio Solutions, Johnson & Johnson, Merck & Co., Inc., Pfizer, and Corcept Therapeutics are the seven Medical stocks to watch today, according to...

Intelligent Bio Solutions Stock Surges 188% On New Manufacturing Partnership

(RTTNews) - Intelligent Bio Solutions Inc. (INBS) shares jumped 187.68%, trading at $11.80, up $7.70, after the company announced a new manufacturing partnership aimed at strengthening global...

Best Value Stocks To Consider - December 31st

Invesco QQQ, Ondas, Intelligent Bio Solutions, ProShares UltraPro Short QQQ, Rocket Lab, CoreWeave, and D-Wave Quantum are the seven Value stocks to watch today, according to MarketBeat's stock...

Intelligent Bio Stock Doubles On New Manufacturing Deal Promising Major Cost Cuts

Intelligent Bio Solutions stock rises after announcing a manufacturing partnership targeting over 40% cost savings, major margin improvement, and expanded global production capacity ahead of planned...

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$15.26
Prev Close	$17.92
Open	$23.00
Dividend Yield	0.00%
50-Day Moving Average	$7.63
Beta	1.39
Avg. Volume	4.97M
PE Ratio	-10.49

52-Week High	$27.50
52-Week Low	$4.03
Market Capitalization	$13.73M
EPS (Annual)	-$2.00
Price to Book	45.02
Revenue Per Employee	$55,500.58
Enterprise Value/EBITDA	N/A

INBS
Intelligent Bio Solutions Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INBS News

INBSIntelligent Bio Solutions Inc